Keros Therapeutics, Inc.
KROS
$11.58
$0.110.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2,250.99% | 8,037.50% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,250.99% | 8,037.50% | -- | -- | -- |
| Cost of Revenue | 29.91% | -63.86% | -73.31% | -78.81% | -83.86% |
| Gross Profit | -5.84% | 64.39% | 73.56% | 79.04% | 84.04% |
| SG&A Expenses | 16.99% | 19.41% | 25.84% | 27.72% | 26.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.04% | 31.67% | 34.81% | 38.80% | 48.18% |
| Operating Income | -24.06% | -31.26% | -34.62% | -38.62% | -48.05% |
| Income Before Tax | -22.26% | -27.45% | -32.81% | -37.84% | -46.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.46% | -27.45% | -32.81% | -37.84% | -46.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.46% | -27.45% | -32.81% | -37.84% | -46.15% |
| EBIT | -24.06% | -31.26% | -34.62% | -38.62% | -48.05% |
| EBITDA | -23.93% | -31.11% | -34.46% | -38.68% | -48.21% |
| EPS Basic | 3.52% | -5.26% | -13.01% | -16.74% | -25.19% |
| Normalized Basic EPS | 3.66% | -5.27% | -13.01% | -16.74% | -25.18% |
| EPS Diluted | 1.58% | -5.42% | -42.33% | -46.95% | -57.25% |
| Normalized Diluted EPS | 3.66% | -5.27% | -13.01% | -16.74% | -25.18% |
| Average Basic Shares Outstanding | 27.13% | 21.34% | 18.71% | 18.79% | 16.69% |
| Average Diluted Shares Outstanding | 27.13% | 21.34% | 18.71% | 18.79% | 16.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
